CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 1.5B 3B 4.5B Q4 '20: 672.9M Q1 '21: 707.7M Q2 '21: 948.1M Q3 '21: 1.2B Q4 '21: 1.5B Q1 '22: 2.1B Q2 '22: 2.6B Q3 '22: 3B Q4 '23: 1.3B Q1 '24: 1.3B Q2 '24: 1.3B Q3 '24: 1.3B Q4 '24: 1.4B Q1 '25: 1.5B Q2 '25: 1.6B Q3 '25: 1.8B Q4 '25: 1.9B Q1 '26: 2.2B Q2 '26: 2.5B Q4 '20 Q3 '21 Q2 '22 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

-150M 0 150M 300M 450M Q4 '21: -79.2M Q1 '22: -52.4M Q2 '22: -18.5M Q3 '22: 7.7M Q4 '22: 22.7M Q1 '23: 57.3M Q2 '23: 145.2M Q3 '23: 198.5M Q4 '23: 257.3M Q1 '24: 291.9M Q2 '24: 323.9M Q3 '24: 334.9M Q1 '22 Q3 '22 Q1 '23 Q3 '23 Q1 '24 Q3 '24

Operating Income TTM

-750M -500M -250M 0 250M 500M 750M Q4 '20: -92.7M Q1 '21: -185.2M Q2 '21: -390.2M Q3 '21: -517.8M Q4 '21: -637M Q1 '22: -605.4M Q2 '22: -526.2M Q3 '22: -451.1M Q4 '22: -286.7M Q1 '23: -278.9M Q2 '23: -205M Q3 '23: -164.6M Q4 '23: -205.3M Q1 '24: -148.3M Q2 '24: -112.3M Q3 '24: -87.4M Q4 '24: -45.7M Q1 '25: -24.3M Q2 '25: -42.1M Q3 '25: -57.7M Q4 '25: -85.5M Q1 '26: -56.9M Q2 '26: -18.4M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-750M -500M -250M 0 250M 500M 750M Q4 '20: -136.4M Q1 '21: -156.6M Q2 '21: -479.7M Q3 '21: -526.9M Q4 '21: -587.8M Q1 '22: -614.8M Q2 '22: -401.6M Q3 '22: -442.5M Q4 '22: -339.6M Q1 '23: -336.7M Q2 '23: -261.1M Q3 '23: -227.1M Q4 '23: -213.4M Q1 '24: -159.9M Q2 '24: -123.7M Q3 '24: -91.4M Q4 '24: -43M Q1 '25: -25.1M Q2 '25: -43.1M Q3 '25: -58.3M Q4 '25: -85.5M Q1 '26: -56.9M Q2 '26: -18.4M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-300M -200M -100M 0 100M 200M 300M Q4 '20: -118.5M Q1 '21: -174.2M Q2 '21: -251.6M Q3 '21: -262.1M Q4 '21: -282.3M Q1 '22: -246.5M Q2 '22: -221.5M Q3 '22: -74.7M Q4 '22: -203.9M Q1 '23: -67.9M Q2 '23: 24.5M Q3 '23: -95.9M Q4 '23: -144.7M Q1 '24: -197.8M Q2 '24: -206.2M Q3 '24: -137.4M Q4 '25: -66.9M Q1 '26: 57.3M Q2 '26: 77M Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '26

Free Cash Flow TTM

-300M -200M -100M 0 100M 200M 300M Q4 '20: -119.2M Q1 '21: -174.7M Q2 '21: -252.1M Q3 '21: -262.6M Q4 '21: -283M Q1 '22: -247.3M Q2 '22: -222.3M Q3 '22: -75.6M Q4 '22: -208.4M Q1 '23: -72.4M Q2 '23: 19.8M Q3 '23: -100.7M Q4 '25: -69M Q1 '26: 54.5M Q2 '26: 74.2M Q4 '20 Q2 '21 Q4 '21 Q2 '22 Q4 '22 Q2 '23 Q4 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 200M 400M 600M Q2 '20: 242.6M Q3 '20: 248.1M Q1 '21: 376.2M Q2 '21: 408.2M Q3 '21: 414.6M Q1 '22: 473M Q2 '22: 476.1M Q3 '22: 477.7M Q1 '23: 478.8M Q2 '23: 479.2M Q3 '23: 480.8M Q1 '24: 486.4M Q2 '24: 495.2M Q3 '24: 490.2M Q1 '25: 497.1M Q2 '25: 509M Q3 '25: 512.7M Q1 '26: 532.5M Q2 '26: 545.4M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.70 -1.80 -0.90 0.00 0.90 1.80 2.70 Q4 '20: -1.40 Q1 '21: -1.53 Q2 '21: -2.32 Q3 '21: -2.42 Q4 '21: -1.43 Q1 '22: -1.46 Q2 '22: -0.90 Q3 '22: -0.98 Q4 '22: -0.71 Q1 '23: -0.70 Q2 '23: -0.54 Q3 '23: -0.47 Q4 '23: -0.44 Q4 '20 Q2 '21 Q4 '21 Q2 '22 Q4 '22 Q2 '23 Q4 '23

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.